Finanzen von Creative Medical Technology Holdings Inc (CELZ)CELZCreative Medical Technology Holdings Inc

Evaluating the bottom line, Creative Medical Technology Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -78.03%, provide a clear picture of how effectively CELZ converts its operational activities into shareholder value.

In the context of the broader market, CELZ competes directly with industry leaders such as NDRA and NVNO. With a market capitalization of $7.45M, it holds a significant position in the sector. When comparing efficiency, CELZ's gross margin of N/A stands against NDRA's N/A and NVNO's N/A. Such benchmarking helps identify whether Creative Medical Technology Holdings Inc is trading at a premium or discount relative to its financial performance.

The company has shown inconsistent revenue, with total revenue of only $3,000 in Q4 2024, and a net income loss of -1,851,074 in the same quarter. The gross margin has been negative, indicating ongoing financial struggles.